ReviewFrontiers in microbiology2018
Immunomodulation as Therapy for Fungal Infection: Are We Closer?
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 63 citations in OpenAlex.
- Temporal shifts in adaptive immunity drive HIV-associated cryptococcal IRIS: mechanisms, models, and therapeutic opportunities.NeuroImmune pharmacology and therapeutics · 2026Article
- Immunomodulation in the Treatment of Disseminated Coccidioidomycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.Frontiers in immunology · 2026Article
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
- Fungal infections in focus: accelerating non-invasive imaging from preclinical insights to clinical breakthroughs.Npj imaging · 2025Review
- Blastemia portrays a poor prognosis in acute leukemia patients with invasive pulmonary aspergillosis.The Journal of infection · 2025Article
- Proteomic profiling reveals immunomodulatory role of IL-33 in ocular bacterial and fungal infections.Infection and immunity · 2025Article
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- CXCL1 and CXCL2: Key Regulators of Host Defense AgainstJournal of inflammation research · 2025Article
- Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.The Journal of antimicrobial chemotherapy · 2024Article
- Humans vs. Fungi: An Overview of Fungal Pathogens against Humans.Pathogens (Basel, Switzerland) · 2024Review
- Adjuvant ArtinM favored the host immunity againstImmunotherapy · 2024Article
- Coccidioidomycosis and Host Microbiome Interactions: What We Know and What We Can Infer from Other Respiratory Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Immunomodulatory Effects of the Pea Defensin Psd1 in the Caco-2/Immune Cells Co-Culture uponInternational journal of molecular sciences · 2023Article
- The Transcriptional Regulation of Genes Involved in the Immune Innate Response of Keratinocytes Co-Cultured withJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- A Fun-Guide to Innate Immune Responses to Fungal Infections.Journal of fungi (Basel, Switzerland) · 2022Review
- Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.Journal of clinical medicine · 2022Review
- A determination of pan-pathogen antimicrobials?Medicine in drug discovery · 2022Review
- Rhino-Orbital Cerebral Mucormycosis in a Patient With Diabetic Ketoacidosis: A Case Report and Literature Review.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal disease (IFD) causes significant morbidity in immunocompromised patients due to their weakened immune system. Immunomodulatory therapy, in synergy with existing antifungal therapy, is an attractive option to enhance their immune system and aid clearance of these opportunistic pathogens. From a scientific and clinical perspective, we explore the immunotherapeutic options to augment standard antifungal drugs for patients with an IFD. We discuss the range of immunomodulatory therapies being considered in IFD - from cytokines, including G-CSF, GM-CSF, M-CSF, IFN-γ, and cytokine agonists, to cellular therapies, consisting of granulocyte transfusion, adoptive T-cell, CAR T-cell, natural killer cell therapies, and monoclonal antibodies. Adjunct pharmaceutical agents which augment the immunity are also being considered. Lastly, we explore the likelihood of the use of probiotics and manipulation of the microbiome/mycobiome to enhance IFD treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.